Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRanjini K. Sundaram

Discussion

Loading...

Member takes

Overview

Multi-omics analysis reveals MGMT silencing enhances tumor response to KL50 over temozolomide in AML, suggesting a new biomarker-driven treatment approach.

Key Points

  • To explore the role of MGMT silencing as a biomarker and its therapeutic implications in acute myeloid leukemia (AML).
  • Conducted multi-omics analysis of AML samples from a tissue biobank and TCGA.
  • Screened various alkylating agents against engineered AML cell lines.
  • Evaluated drug efficacy in primary patient-derived xenografts (PDXs) engrafted in immunocompromised mice.
  • Approximately 25-30% of AMLs exhibited high MGMT promoter methylation and low expression.
  • KL50 demonstrated superior efficacy compared to temozolomide in MGMT-silenced AML models.
  • Both KL50 and temozolomide induced complete remission in MGMT-silenced PDXs, whereas MGMT-proficient PDXs did not respond.

Cite This Study

Ranjini K. Sundaram (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d010https://doi.org/10.1182/blood-2025-322
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Novel Strategies for Improved Treatment of O6-Methylguanine-DNA Methyltransferase Promoter-Methylated Glioma2025 · 4 citations
  2. 2Genetic and epigenetic landscape of O6-methylguanine-DNA methyltransferase (MGMT): implications for DNA repair and cancer therapeutics2025 · 12 citations
  3. 3XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in IDH wildtype glioblastoma2025 · 2 citations
  4. 4Selective disruption of DNMT1/ELK1 interactions induces DGKI re-expression and promotes temozolomide sensitivity of MGMTmethylated/DGKImethylated glioblastoma2025 · 3 citations
  5. 5Circadian variation in MGMT promoter methylation and expression predicts sensitivity to Temozolomide in glioblastoma2025